Pfizer Prepared to Reshore Manufacturing if Trump Makes Good on Tariff Threats
Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing facilities across the U.S. in five years.
Merck opens manufacturing facility in North Carolina amid Trump's tariff threats
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats.
Merck opens $1B vaccine plant in North Carolina
Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.
Merck Opens Vaccine Manufacturing Facility in North Carolina
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's tariff threats. Drugmakers have been exploring the possibility of government-granted exemptions for domestically manufactured medicines since Trump has threatened to impose 25% tariff on pharmaceutical imports.
Merck opens $1 billion addition in north Durham to boost production of popular vaccine
The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road. This new plant will manufacture the HPV vaccines Gardasil and Gardasil 9,
Pfizer could move outside manufacturing to the US, says CEO
(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in ...
Pfizer CEO says he's prepared to shift manufacturing to the U.S. amid tariff threats
CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if ...
STAT9d
Pharmalittle: We’re reading about Pfizer navigating tariffs, Makary’s pledge to avoid conflicts, and more
Pfizer CEO Albert Bourla said the drugmaker might move overseas manufacturing to its plants in the U.S. as Trump threatens ...
Pfizer could use existing US manufacturing to counter potential tariff hit
By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its ...
Devdiscourse10d
Pfizer's Strategic Manufacturing Shift Amidst Tariff Threats
Pfizer CEO Albert Bourla announced the possibility of shifting overseas manufacturing to U.S. plants. This response is due to ...
Pfizer may move outside manufacturing plants to US: CEO amid tariff threats
The US president has imposed a 10 per cent tariff across all Chinese imports into the US and proposed a 25 per cent levy on ...
Pfizer could use existing U.S. production to counter tariff hit, Reuters reports
Pfizer (PFE) may move overseas manufacturing to its existing plants in the U.S., if required, as the Trump administration threatens numerous ...
Nature24d
Pfizer stakes a claim in plant cell–made biopharmaceuticals
On December 1, Pfizer became the first big pharma to commit to take to market a late-stage biologic drug produced in plant cells. It acquired rights to taligurase alfa, a form of the enzyme ...